Skip to main content
Clinical Trials/NCT04418557
NCT04418557
Completed
Not Applicable

COVID-19 and Obstetric Transmission

University Hospitals Cleveland Medical Center1 site in 1 country64 target enrollmentApril 28, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID
Sponsor
University Hospitals Cleveland Medical Center
Enrollment
64
Locations
1
Primary Endpoint
Presence of COVID-19 virus
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The aim of this study is to capture data, laboratory markers, and clinical outcomes of obstetric and neonatal outcomes in cases of COVID-19 during pregnancy and of pregnancies exposed to a COVID-19 vaccine in Cuyahoga County.

Detailed Description

A review of the 55 cases of obstetric COVID-19 cases world-wide demonstrate the following fetal complications of COVID-19: miscarriage (2%), intrauterine growth restriction (IUGR; 10%), pre-eclampsia, and pre-term birth (39%). In Wuhan, China, nine women who were COVID-19 positive were surveilled for vertical transmission and overall obstetric and early neonatal outcomes. Amniotic fluid, umbilical cord blood, and neonatal throat swabs were collected at the time of delivery, and breastmilk samples were collected after lactation commenced. There was no viral detection of COVID-19 demonstrated.2 However, two neonates in the United Kingdom have tested positively for COVID-19 after delivery from an infected mother. Most recently, antibodies were detected (IgM and IgG) in the serum of a neonate born via cesarean delivery to a known positive mother. Therefore, vertical transmission has not been completely ruled out. Additionally, infection at varying times of pregnancy has not been well delineated or correlated to neonatal or maternal outcomes at time of delivery. Therefore, there is a need to continue surveying and documenting clinical findings in obstetric COVID-19 cases. This study will follow pregnant women who are diagnosed during any point of their pregnancy with COVID-19 and those who were vaccinated. during pregnancy. The aim will be to evaluate maternal and neonatal specimens for the presence of COVID-19 virus, immune and cellular response.

Registry
clinicaltrials.gov
Start Date
April 28, 2020
End Date
July 15, 2021
Last Updated
3 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Rachel Pope

Assistant Professor

University Hospitals Cleveland Medical Center

Eligibility Criteria

Inclusion Criteria

  • COVID-19 infection at any time of the pregnancy, or presumed case by symptoms and direct contact with a positive case
  • Pregnancy documented by ultrasound

Exclusion Criteria

  • COVID-19 infection before or after pregnancy
  • Person under investigation, but not a presumed or known positive case

Outcomes

Primary Outcomes

Presence of COVID-19 virus

Time Frame: At time of delivery

Viral presence in any of the collected specimens

Secondary Outcomes

  • Presence of antibodies to COVID-19 virus(At time of delivery and 24 hours of life of the newborn)

Study Sites (1)

Loading locations...

Similar Trials